This program creates value far exceeding direct financial rewards. By combining tangible
token rewards with profound emotional and mental health benefits, the Award Program
delivers extraordinary societal value over time.
Dual-Impact Design: Recipients receive tangible rewards that provide
immediate liquidity for critical needs, while their blockchain-preserved stories create
exponential emotional value by inspiring countless others facing similar battles.
2026 Launch Funding Sensitivity
The current enterprise page now models 2026 ARR at $10.8M in the conservative case, $15M
in the moderate case, and $22.8M in the aggressive case. Holding the rewards program at
the same launch intensity puts the year-one funding envelope at roughly $6.3K-$13.3K,
with the current $8.75K initial proof-cohort budget still matching the
moderate case.
Enterprise-Linked Planning Snapshot
- 2026 Launch Budget: $6.3K-$13.3K across conservative to
aggressive enterprise scenarios
- 2026-2030 Direct rewards Capacity: $1.12M-$2.19M using the same
0.0583% launch-intensity ratio
- Emotional and Mental Health Value: $2.6M+ as a conservative
10-year floor
- Multi-Disease Expansion: Expands in four rollout waves, moving from the initial proof cohort to all 8 disease and condition communities by Q2 2027
Calculating Emotional Value in Dollar Terms
We use a health economics approach to quantify the monetary value of non-financial
outcomes including mental health improvements, reduced isolation, and quality-of-life
gains.
Per-Recipient Emotional Value: $5,000
1. Mental Health Treatment Costs Avoided: $2,000-$3,000
- Recognition reduces depression and anxiety
- Saves therapy sessions and medication needs
- Improves treatment compliance and outcomes
2. Reduced Isolation Value: $1,000-$1,500
- Connection to community
- Improved quality of life
- Reduced readmissions and better health outcomes
3. Family Impact: $1,500
- Reduced caregiver burden
- Lower family anxiety and stress
- Reduced burnout
4. Community Inspiration: Exponential Growth
- Each blockchain story can be viewed by 100 to 500 people per year
- Each viewer gains measurable inspiration and hope value
- Permanent preservation ensures lasting impact
Conservative Methodology
Our $5,000 per-recipient estimate is deliberately modest. Actual
mental health treatment for chronic disease patients often costs substantially more.
We use conservative figures to keep projections defensible while still showing the
scale of impact.
Sources and Methodology Notes
Clinical evidence base: The morale, hope, social-support, and
dignity claims on this page are grounded in the literature cited in Mental
Health Benefits, including Luszczynska et al. (Psychooncology,
2013; PMID: 23097417), Sihvola et al. (Eur J Oncol Nurs, 2022; PMID:
34844135), and dignity-therapy meta-analyses (PMIDs: 31808977, 31243850, 35635908).
Economic framing: The $5,000 per-recipient emotional-value proxy is
a conservative planning estimate, not a formal cost-effectiveness or QALY model. It
is built from modest ranges for avoided mental-health support costs, reduced
isolation burden, caregiver spillover benefits, and downstream inspiration value
from permanently accessible stories.
Forecast basis: The launch-budget, 2026-2030 capacity, and scaling
examples below are derived from the current enterprise scenario framework: 2026 ARR
of $10.8M, $15M, and $22.8M; 2027 moderate ARR of $130M; 2028 moderate ARR of $400M
with an illustrative $4.0B valuation; and 2030 scenarios of $830M+, $1.3B, and
$1.67B ARR.
Application rule: rewards budgets are calculated by applying the
current moderate launch ratio of 0.0583% of ARR, based on the present $8.75K plan on
$15M ARR, across the relevant enterprise milestones.
Enterprise-Linked rewards Capacity
The table below replaces the old placeholder market-cap scenarios with values tied
directly to the enterprise forecast. It keeps the same launch intensity as the current
$8.75K moderate 2026 plan, which allocates 0.0583% of ARR to the rewards program.
| Scenario |
2026 ARR |
2028 IPO Valuation |
2026-2030 Direct rewards Capacity |
Planning Read |
| Conservative |
$10.8M |
$2.9B |
$1.12M |
Supports a disciplined initial proof cohort with measured expansion through the Q2 2027 completion timeline. |
| Moderate |
$15M |
$4.0B |
$1.53M |
Matches the current $8.75K initial proof-cohort budget and gives room for multi-disease
expansion. |
| Aggressive |
$22.8M |
$5.6B |
$2.19M |
Creates headroom for faster expansion and materially larger annual award
pools. |
Method: 2026-2030
direct rewards capacity applies the current launch intensity of 0.0583% of ARR to each
enterprise scenario from 2026 through 2030, then sums those annual budgets.
Source basis:
enterprise scenario milestones are taken from the current Enterprise and Value
Proposition planning pages, including the 2028 illustrative 10x ARR valuation
framework.
Clinical Literature Reference Links
- Luszczynska et al., 2013: Social support and quality of life in
lung cancer patients. PubMed PMID 23097417
- Sihvola et al., 2022: Resilience, hope, and social support in
colorectal cancer patients. PubMed PMID 34844135
- Li et al., 2020: Meta-analysis of dignity therapy in advanced
cancer and palliative settings. PubMed PMID 31808977
- Xiao et al., 2019: Dignity therapy evidence synthesis for
psychological and quality-of-life outcomes. PubMed PMID 31243850
- Zhang et al., 2022: Meta-analysis of dignity-focused
interventions in palliative and cancer care. PubMed PMID 35635908
Planning and Forecast Sources
- Enterprise Forecast: Source for 2026, 2027, 2028, and 2030 ARR
scenario anchors, plus the illustrative 10x ARR valuation framework. Open Enterprise Page
- Value Proposition: Source for synced year-one award structure
and investor-facing framing of the rewards program. Open Value Proposition Page
- rewards Methodology Notes: See the source and methodology notes
above for the conservative emotional-value proxy and award-intensity ratio
logic.
- Mental Health Benefits Evidence Box: See the Mental Health
Benefits section on this page for the inline morale, resilience, dignity, and
social-support literature summary.
